Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): National University Hospital Parkway Cancer Centre Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Melissa Ooi Gaik Ming Dr Colin Phipps Diong Dr Lao Zhentang

Published by HT Digital Content Services with permission from Health Daily Digest....